Status:

ACTIVE_NOT_RECRUITING

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Lead Sponsor:

Hoffmann-La Roche

Conditions:

MASH

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated...

Eligibility Criteria

Inclusion

  • Body mass index within the range of \>= 25 and \<=45 kilograms per square meter (kg/m\^2)
  • MASH with fibrosis score of F3 or F4 confirmed by transient elastography measurement \>=12.0 kPa and \<=25.0 kPa
  • Agreement to adhere to the contraception requirements

Exclusion

  • Weight gain or loss \>5% in the 3 months prior to baseline or \>10% in the 6 months prior to baseline
  • Bariatric surgery within 1 year prior to baseline
  • Current signs or prior history of decompensated liver disease
  • Complications or clinical evidence of portal hypertension
  • Lack of peripheral venous access
  • Other causes of liver disease based on medical history and/or centralized review of liver histology
  • History of liver transplantation
  • Current or prior history of hepatocellular carcinoma (HCC)
  • Uncontrolled hypertension
  • Concomitant Type 1 diabetes, or Type 2 diabetes with HbA1c \>10%
  • History of malignancy within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
  • Current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening
  • Initiation of a medication of an antidiabetic, weight loss, lipid-modifying or anti-depressant drug class
  • Active tuberculosis requiring treatment within the 12 months prior to baseline
  • History of organ transplant

Key Trial Info

Start Date :

April 14 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2026

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06903065

Start Date

April 14 2025

End Date

December 30 2026

Last Update

January 8 2026

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

Adobe Clinical Research, LLC

Tucson, Arizona, United States, 85712

2

Gastro Health Research - Miami

Miami, Florida, United States, 33176

3

Gastrointestinal Specialists of Georgia, PC

Marietta, Georgia, United States, 30060

4

Delta Research Partners, LLC (Bastrop)

Bastrop, Louisiana, United States, 71220